Company Overview and News
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Few schools teach financial literacy, but there could be another way for Americans to learn this crucial knowledge.
One month ago, Facebook seemed to be on the brink of demise, with CEO Mark Zuckerberg testifying before Congress about a data-harvesting scandal that affected millions of users.
LLNW TXN UNH COUP
Danaher: "OK, Danaher's one of the most well-managed companies in the country. I tell club members of ActionAlertsPlus.com [that] this may be the finest company we own in the entire portfolio of the charitable trust right here, right now. Did you see they're trying to buy the $20 billon life science division of GE? [That] made me feel like maybe, indeed, GE is done going down."
LLNW GIS TXN STX GWP
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED7!E+T=R;W5P+U,O5')A;G-P87)E;F-Y M+T-3+T1E=FEC95)'0CX^+U1A8G,O4R]3=')U8W1087)E;G1S(# ^/@T*96YD M;V)J#0HT(# @;V)J#0H\/"]&:6QT97(O1FQA=&5$96-O9&4O3&5N9W1H(#(S M,C4^/@T*
The average stock that has reported earnings this season (since 4/10) has fallen in price on its earnings reaction day (the first trading day following a stock's earnings report).
IBM PM FCX NFLX AXP PIR ISRG SKX SC LLNW ERIC SIX URI CSX TRVG BBBY MMM
The average stock that has reported earnings this season (since 4/10) has fallen in price on its earnings reaction day (the first trading day following a stock’s earnings report).
LLNW PM URI ISRG
Document Table of Contents
Good day, ladies and gentlemen. Welcome to the Limelight Networks 2018 First Quarter Financial Results Conference Call. [Operator Instructions].
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET